Phase 3 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with stomach (gastric) cancer or cancer at the junction where the esophagus meets the stomach (a specific type called Siewert type 2 or 3), confirmed by a tissue sample (biopsy)
- People whose cancer has reached a certain stage of spread within or near the stomach area, but has not spread to distant parts of the body (no distant metastases), and has not invaded certain major blood vessels or nearby structures such as the main liver artery, the celiac trunk, part of the splenic artery, the aorta, or the head of the pancreas (confirm with trial site)
- People who are in generally good physical condition and able to carry out daily activities, rated 0 or 1 on a standard medical fitness scale (meaning fully active or able to do light work)
- People whose cancer is located in specific areas, including the junction of the esophagus and stomach, or various parts of the stomach (upper, middle, lower, or outlet)
- People whose cancer may have grown into nearby structures such as the lower food pipe, diaphragm, liver, part of the pancreas, abdominal wall, parts of the intestine, the spleen, or part of the splenic artery
- People who agree to take part in this research study
Who may not be able to join:
- People who have had a different type of cancer in another part of the body within the last 5 years, where treatment was aimed at fully removing or curing that cancer
- People who have other health conditions or physical circumstances that would make it unsafe or unsuitable for them to receive chemotherapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mykyta Pepenin, MD, National Cancer Institute (NCI)
Phone: +380959448858
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
All 8 planned FLOT cycles tolerance rate.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.